.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Argus Health
Chinese Patent Office
Teva
Chubb
Healthtrust
US Department of Justice
Fish and Richardson
Citi
QuintilesIMS

Generated: June 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,687,516

« Back to Dashboard

Which drugs does patent 7,687,516 protect, and when does it expire?


Patent 7,687,516 protects ARGATROBAN IN SODIUM CHLORIDE and is included in one NDA.

This patent has seven patent family members in five countries.

Summary for Patent: 7,687,516

Title:Alcohol free formulation of argatroban
Abstract: An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.
Inventor(s): Palepu; Nageswara R. (Southampton, PA)
Assignee: Eagle Pharmaceuticals, Inc. (Woodcliff Lake, NJ)
Application Number:11/973,485
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eagle Pharms
ARGATROBAN IN SODIUM CHLORIDE
argatroban
INJECTABLE;IV (INFUSION)022434-001Jun 29, 2011RXYesYes7,687,516► SubscribeY METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,687,516

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,589,106Alcohol free formulation of argatroban► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,687,516

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO)2008039473► Subscribe
Japan5624766► Subscribe
Japan2010504971► Subscribe
European Patent Office2083823► Subscribe
China101516370► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Baxter
Teva
Merck
AstraZeneca
Healthtrust
Express Scripts
US Department of Justice
Dow
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot